Armada Acquisition to merge with Brains Bioceutical in US$750M Nasdaq deal
Under the proposed terms, existing Brains Bioceutical shareholders will roll over their entire equity interests into the newly listed company.
USA—Armada Acquisition has agreed to merge with Brains Bioceutical in a transaction valuing the pharmaceutical company at about US$750 million, paving the way for the combined business to list on the Nasdaq stock exchange in 2027.
Following completion, the combined entity will operate as Brains Therapeutics and trade its common shares on Nasdaq under the ticker symbol BAPI.
The transaction remains subject to regulatory approvals, registration statement effectiveness, and shareholder votes from both companies.
The boards of directors of both organisations have unanimously approved the agreement, with completion targeted for the second quarter of 2027.
Under the proposed terms, existing Brains Bioceutical shareholders will roll over their entire equity interests into the newly listed company.
Pharmaceutical manufacturing and cannabinoid portfolio
Brains Bioceutical manufactures active pharmaceutical ingredients (APIs) and develops pharmaceutical therapies.
Its operations include an EU Good Manufacturing Practice (EU-GMP) certified facility operated through its wholly owned subsidiary, BSPG Laboratories.
The company manufactures or develops several cannabinoid-based ingredients, including cannabinol (CBN), cannabidiol (CBD), cannabigerol (CBG), delta-8-tetrahydrocannabinol (D8-THC), and delta-9-tetrahydrocannabinol (D9-THC).
Its portfolio also covers medical products and pharmaceutical intermediates.
Brains Bioceutical has regulatory filings, controlled-substance licences, and clinical research experience across Australia, Brazil, Japan, the United Arab Emirates, the UK, the European Union, and the US.
Beyond pharmaceutical manufacturing, it supplies ingredients to the animal health and nutraceutical sectors, giving it access to markets outside conventional drug development.
Clinical pipeline and research partnerships
The company’s clinical development portfolio includes an oral capsule targeting epilepsy, an early-stage programme for sleep disorders, and global rights to an extended-release formulation of methazolamide for glaucoma.
It also supplies clinical materials for a National Institutes of Health (NIH)-funded study investigating the potential use of cannabinoids in treating opioid use disorder.
Brains Bioceutical chairman and CEO Rick Brar described the transaction as an important milestone in the company’s development.
He said the business had spent several years establishing its manufacturing capabilities, regulatory infrastructure, and scientific expertise to support its expansion in the pharmaceutical market.
Brar noted that the company has moved beyond early-stage compound development, building a pharmaceutical-grade manufacturing platform, commercial customer relationships, regulatory experience, and a pipeline of proprietary and partnered drug programmes.
The proposed Nasdaq listing comes as cannabinoid-based pharmaceutical developers seek to advance clinical programmes and establish regulated manufacturing and commercial supply capabilities.
For Brains Bioceutical, the transaction provides a route to the public capital markets as it pursues the development of its drug pipeline and expands its pharmaceutical ingredient business.
Be the first to leave a comment